Upcoming Study

Patients with newly diagnosed T1D

Patients, like yours, between the ages of 5-35 who have been recently diagnosed (within the first 6-9 weeks) may be eligible to take part in a bold new upcoming study of an investigational single dose disease modifying T1D therapy.

Contact Us

Learn more about the upcoming SAFEGUARD study and if it will be right for your patients.

About The Safeguard Study

SAFety and Efficacy of Human Antithymocyte ImmunoGlobUlin
SAB-142 ARresting Progression of Type 1 Diabetes

The SAFEGUARD study is a phase 2B, randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy and safety of SAB-142 for the delay of progression of type 1 diabetes in new/recent onset patients with Stage 3 T1D.

Our objective for the SAFEGUARD trial is to evaluate the change in stimulated C-Peptide response following the mixed meal tolerance test at Month 12 following a single dose of SAB-142.

Study Plan
Find out more about the study plan

Who is eligible?

  • Male and female patients
  • Ages 5-35 years old
  • Diagnosed with new or recent onset stage 3 T1D

Currently there are approximately 50 trial sites across multiple countries, including: Australia, New Zealand, USA, Canada, UK, and countries within the European Union.

Contact Us
For study sites in your area

Contact Us

For eligibility information for the upcoming SAFEGUARD Study email us at [email protected]

  • SAB-142 directly targets several lymphocyte subsets thought to be involved in the pathophysiology of type 1 diabetes.
  • SAB-142 is an anti-thymocyte immunoglobulin with a mechanism of action (MoA)  analogous to rabbit ATG.
  • SAB-142 is a fully human immunoglobulin and anticipated to have an improved safety and low immunogenicity profile without a risk of serum sickness associated with administration of non-human immunoglobulins.

About SAB-142

SAB-142 is being developed as a potentially disease-modifying immunotherapy aimed at delaying the onset and progression of T1D. SAB-142 is not another insulin nor is it for chronic disease management, it is potentially a disease-modifying therapy for T1D, envisioned to be administered once a year.

SAB-142 will potentially address the underlying cause of T1D: an immune response where the immune system mistakenly attacks insulin-producing beta cells in the pancreas, by helping preserve beta cell function over time.

Read More
About our science